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At the time of writing, ten trainees had attended the on-call
shift. All participants completed a pre- and post-session question-
naire. The on-call shift was a useful learning experience (median
score 9), and significantly increased perceived preparedness for
on-call work from 3/10 to 7/10 (p < 0.001). Confidence was sig-
nificantly improved in seven domains, most markedly in seclusion
reviews, prescribing and mental health act tasks.
Conclusion. The psychiatry virtual-on-call programme fills a
niche in the training curriculum and is perceived by trainees to
be a useful learning experience. The introductory lecture
improved confidence in several domains, but not as effectively
as the on-call shift. The on-call shift was well received by partici-
pants and significantly improved confidence in 7/10 domains. In
summary, the virtual-on-call experience improves preparedness
for out-of-hours psychiatry work. Follow-up of participants at
the end of their psychiatry rotation will ascertain if they felt the
programme to be useful during out-of-hours work.
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Aims. This study examined lithium results and requesting pat-
terns over a 6-year period, and compared these to guidance.
Background. Bipolar disorder is the 4th most common mental
health condition, affecting ∼1% of UK adults. Lithium is an
effective treatment for prevention of relapse and hospital admis-
sion, and is recommended by NICE as a first-line treatment.
We have previously shown in other areas that laboratory test-
ing patterns are highly variable with sub-optimal conformity to
guidance.
Method. Lithium requests received by Clinical Biochemistry
Departments at the University Hospitals of North Midlands,
Salford Royal Foundation Trust and Pennine Acute Hospitals
from 2012–2018 were extracted from Laboratory Information
and Management Systems (46,555 requests; 3,371 individuals).
We categorised by request source, lithium concentration and
re-test intervals.
Result. Many lithium results were outside the NICE therapeutic
window (0.6–0.99mmol/L); 49.3% were below the window and
6.1% were above the window (median [Li]:0.61mmol/L). A small
percentage were found at the extremes (3.2% at <0.1mmol/L,
1.0% at >1.4mmol/L). Findings were comparable across all sites.
For requesting interval, there was a distinct peak at 12 weeks,
consistent with guidance for those stabilised on lithium therapy.
There was no peak evident at 6 months, as recommended for
those <65 years old on unchanging therapy. There was a peak at
0–7 days, reflecting those requiring closer monitoring (e.g. treat-
ment initiation or results suggesting toxicity).
However, 77.6% of tests were requested outside expected testing
frequencies.
Conclusion.We showed: (a) lithium levels are often maintained
at the lower end of the NICE recommended therapeutic range
(and the BNF range: 0.4-1.0mmol/L); (b) patterns of lithium
results and testing frequency are comparable across three sites
with differing models of care; (c) re-test intervals demonstrate
a noticeable peak at the recommended 3-monthly interval, but
not at 6-monthly intervals; (d) Many tests were repeated outside
these expected frequencies (contrary to NICE guidance).
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Aims. Lithium was first found to have an acute antimanic effect
in 1948 with further corroboration in the early 1950s. It took
some time for lithium to become the standard treatment for
relapse prevention in bipolar affective disorder. In this study,
our aims were to examine the factors associated wtih the likeli-
hood of maintaining lithium levels within the recommended
therapeutic range and to look at the stability of lithium levels
between blood tests. We examined this relation using clinical
laboratory serum lithium test requesting data collected from
three large UK centres, where the approach to managing patients
with bipolar disorder and ordering lithium testing varied.
Method. 46,555 lithium rest requests in 3,371 individuals over
7 years were included from three UK centres. Using lithium
results in four categories (<0.4 mmol/L; 0.40–0.79 mmol/L;
0.80–0.99 mmol/L; ≥1.0 mmol/L), we determined the proportion
of instances where, on subsequent testing, lithium results
remained in the same category or switched category. We then
examined the association between testing interval and proportion
remaining within target, and the effect of age, duration of lithium
therapy and testing history.
Result. For tests within the recommended range (0.40–0.99
mmol/L categories), 84.5% of subsequent tests remained within
this range. Overall 3-monthly testing was associated with 90%
of lithium results remaining within range compared with 85%
at 6-monthly intervals. At all test intervals, lithium test result his-
tory in the previous 12-months was associated with the propor-
tion of next test results on target (BNF/NICE criteria), with
90% remaining within range target after 6-months if all tests in
the previous 12-months were on target. Age/duration of lithium
therapy had no significant effect on lithium level stability.
Levels within the 0.80–0.99 mmol/L category were linked to a
higher probability of moving to the ≥1.0 mmol/L category
(10%) than those in the 0.40–0.79 mmolL group (2%), irrespective
of testing frequency. Thus prior history in relation to stability of
lithium level in the previous 12 months is a predictor of future
stability of lithium level.
Conclusion. We propose that, for those who achieve 12-months
of lithium tests within the 0.40–0.79mmol/L range, it would be
reasonable to increase the interval between tests to 6 months,
irrespective of age, freeing up resource to focus on those less con-
cordant with their lithium monitoring. Where lithium level is
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0.80–0.99mmol/L test interval should remain at 3 months. This
could reduce lithium test numbers by 15% and costs by ∼$0.4m p.a.
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Aims. To review the ECGs of all patients referred to MAT services
over the preceding 5 year period.
Background. Neurodegenerative conditions such as Alzheimer’s
Disease can be treated with Acetylcholinesterase Inhibitors
(AChEI) to slow down cognitive decline. Side effects of AChEIs
include bradycardia, syncope and cardiac conduction disorders.
An electrocardiograms (ECG) is completed prior to memory
assessment team (MAT) medical assessments to screen for
those who may be at risk of the cardiac side effects of AChEIs.
ECGs may be included in the initial referral to the service or com-
pleted by the MAT. Given the predominantly elderly population
referred to the MATs service, other incidental abnormalities are
to be expected. Not all MAT referrals that are screened by mem-
ory nurses reach the threshold to be reviewed by the medical team
and therefore not all ECGs are routinely reviewed, potentially
missing clinically significant abnormalities.
Result. A total of 1795 patients were identified as being referred
to a single mental health unit in the North West on England
over a five-year period. 781 (44%) of the patients had an ECG
completed by the MAT, of which 452 (58%) showed an abnormal-
ity. Significant abnormalities that were previously unknown to the
patients’ primary care provider include eight cases of Atrial
Fibrillation (AF), four cases of Trifasciular Block, and 19 cases
of Left Ventricular Hypertrophy (LVH). 64 (8%) of patients
who had an ECG by the MAT had a bradycardia.
Conclusion. In addition to identifying abnormalities that could
interfere with memory medication, this audit showed that over
half of the ECGs completed by the MAT had an atypical trace.
Cardiology was consulted to identify which abnormalities were
considered clinically significant and if not already known, the
general practitioner (GP) was informed. A change in the local ser-
vice means that all ECGs completed by the MAT are now
screened at point of filling into the notes, so any future abnormal-
ities are identified and followed up immediately.
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Aims. Few studies have investigated the COVID-19 pandemic’s
effect on children and adolescents with obsessive compulsive dis-
order (OCD), who are thought to be particularly vulnerable. This
study aims to investigate whether the COVID-19 pandemic is
associated with increased referral of young people with OCD in
one area of London and determine if COVID-19 has been asso-
ciated with change in symptom severity and treatment offered
in recent years.
Method. A retrospective study was conducted using clinical ser-
vice data investigating 58 young people (8–17 years) referred
and assessed in CNWL NHS Foundation Trust CAMHS, before
and during the COVID-19 pandemic in 2020 (months March–
October 2018–2020). Changes in symptom severity were mea-
sured using the health of the nation outcome scale for children
and adolescents (HoNOSCA). Total HoNOSCA and three
HoNOSCA items were used; emotional symptoms, family rela-
tionships and school attendance. Patient clinical records were
reviewed to assess if COVID-19 had exacerbated OCD symptoms.
The type of treatment offered (cognitive behavioural therapy
-CBT- only vs combined CBT and medication) was also com-
pared. Analysis was carried out using Chi-square, Kruskal–
Wallis and Mann–Whitney U tests.
Result. 26 (5.62%) initial assessments to CAMHS were related to
OCD in 2020, compared to 12 (1.30%) and 20 (2.27%) assess-
ments pre-pandemic (2018 and 2019), showing a significant
increase in the proportion of OCD cases (X2 (1, N = 58) = 20.3,
p < .001). There was no significant difference in total
HoNOSCA, emotional, family relationships, or school attendance
scores on initial assessment. However, 69.2% of clinical records in
2020 showed symptom worsening over the COVID-period, com-
pared to 30.8% of cases assessed pre-pandemic.There was a sig-
nificant difference between the type of treatment offered before
and during COVID-19 (X2 (2, N = 58) = 12.7, p = .002), with a
higher proportion of patients who were referred to CAMHS for
OCD but discharged without treatment before the pandemic
(37.5% vs 0%). While CBT only remains the most frequent treat-
ment offered, combined treatment was more frequent during the
pandemic, although this difference was not significant.
Conclusion. The proportion of OCD-related initial assessments
in CAMHS increased during the pandemic despite the overall
number of referrals falling. Furthermore, fewer cases were dis-
charged without treatment in CAMHS during this period.
Given this, and that many were reported to have deteriorated dur-
ing the pandemic, services will likely need to address the increased
burden of more severe cases. Further research is warranted to
assess the generalisability of our findings.
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Aims. This evaluation aimed to identify patient, practitioner and
infrastructural barriers to initiation of clozapine treatment in
patients with treatment-resistant schizophrenia (TRS). In
response to recent research supporting use of clozapine as the
most effective treatment for patients with TRS, concerted efforts
have been made to establish why clozapine is underutilised in
the NHS. Following a study conducted by South London and
Maudsley NHS Foundation Trust, which identified barriers and
made recommendations, this evaluation aimed to identify barriers
to initiation of clozapine in patients under the care of Mersey
Care NHS Foundation Trust.
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